Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Neurocrine ( (NBIX) ).
On April 5, 2026, Neurocrine agreed to acquire Soleno Therapeutics via a cash tender offer at $53 per share, valuing the deal at about $2.9 billion and representing sizable premiums to Soleno’s recent trading levels. The transaction, funded with cash on hand and modest pre-payable debt, is expected to close within 90 days of the April 6, 2026 announcement, subject to majority tender, antitrust clearance and other customary conditions, after which Soleno will become a wholly owned subsidiary.
The acquisition brings Soleno’s VYKAT XR, the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, into Neurocrine’s portfolio following a strong 2025 U.S. launch that generated $190 million in revenue. By adding a durable, IP-protected rare disease asset to INGREZZA and CRENESSITY, Neurocrine aims to solidify its leadership at the intersection of neuroscience and endocrinology, diversify and strengthen its high-growth revenue base, and capture cost synergies through integration of Soleno’s operations.
The merger agreement includes standard tender conditions, no financing contingency, and reciprocal provisions on antitrust-related termination fees, with Soleno facing a $95.25 million break fee if it accepts a superior bid and Neurocrine owing a $141.5 million reverse break fee if antitrust hurdles block closing. Soleno’s board has recommended the offer, backed by tender and support agreements from key insiders and no-shop restrictions that nevertheless allow the company, under fiduciary-out provisions, to respond to bona fide superior proposals subject to Neurocrine’s matching rights.
The most recent analyst rating on (NBIX) stock is a Buy with a $177.00 price target. To see the full list of analyst forecasts on Neurocrine stock, see the NBIX Stock Forecast page.
Spark’s Take on NBIX Stock
According to Spark, TipRanks’ AI Analyst, NBIX is a Outperform.
The score is driven primarily by strong financial performance (high margins, strong cash generation, and low leverage) and a positive earnings-call outlook with continued growth guidance and solid profitability/cash. The main offsets are mixed technical momentum (negative MACD, below key mid-term averages) and a relatively high P/E with no dividend yield support.
To see Spark’s full report on NBIX stock, click here.
More about Neurocrine
Neurocrine Biosciences, Inc. is a Nasdaq-listed biopharmaceutical company focused on discovering, developing and commercializing treatments for under-addressed neurological, psychiatric, endocrine and immunological disorders. Its commercial portfolio includes first-in-class therapies such as INGREZZA for tardive dyskinesia and Huntington’s chorea, and CRENESSITY for classic congenital adrenal hyperplasia, with an expanding focus on endocrinology and rare diseases.
Average Trading Volume: 1,128,948
Technical Sentiment Signal: Buy
Current Market Cap: $13.21B
Learn more about NBIX stock on TipRanks’ Stock Analysis page.